Dr Hayden Bell
Dr Helen Blair
Samantha Jepson Gosling
Dr Martin Galler
Dan Astley
et al. | Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia | 2024 |
|
Dr Dino Masic
Dr Hayden Bell
Dr Frederik van Delft
Professor Julie Irving
| Selection of dormant cells during treatment of T-lineage lymphoblastic leukemia and CREB as a therapeutic target | 2024 |
|
Dr Sarah Fordham
Dr Wei-Yu Lin
Dr Helen Blair
Dr Claire Elstob
Dr Hayden Bell
et al. | Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia | 2023 |
|
Dr Dino Masic
Kayleigh Fee
Dr Hayden Bell
Marian Case
Juan Ojeda Garcia
et al. | Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia | 2023 |
|
Dr Jill Hunter
Dr Nicola Hannaway
Scott Kerridge
Dr Saimir Luli
Dr Jacqueline Butterworth
et al. | Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway | 2022 |
|
